Display options
Cite
Nagamatsu F, Satoh S, Ogiwara Y, et al. Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension. Clin Pediatr Endocrinol. 2019;28(2):25-30doi: 10.1297/cpe.28.25.
Nagamatsu, F., Satoh, S., Ogiwara, Y., Shimura, K., Shimada, A., Hachiya, R., & Hasegawa, Y. (2019). Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension. Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology, 28(2), 25-30. https://doi.org/10.1297/cpe.28.25
Nagamatsu, Fusa, et al. "Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension." Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology vol. 28,2 (2019): 25-30. doi: https://doi.org/10.1297/cpe.28.25
Nagamatsu F, Satoh S, Ogiwara Y, Shimura K, Shimada A, Hachiya R, Hasegawa Y. Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension. Clin Pediatr Endocrinol. 2019;28(2):25-30. doi: 10.1297/cpe.28.25. Epub 2019 Apr 24. PMID: 31037020; PMCID: PMC6476948.
Copy Download .nbib Format: NLM
Share it on

Clin Pediatr Endocrinol. 2019;28(2):25-30. doi: 10.1297/cpe.28.25. Epub 2019 Apr 24.

Treatment of adrenal crisis in patients with primary hypoadrenalism can lead to hypertension.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology

Fusa Nagamatsu, Satoko Satoh, Yasuko Ogiwara, Kazuhiro Shimura, Aya Shimada, Rumi Hachiya, Yukihiro Hasegawa

Affiliations

  1. Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

PMID: 31037020 PMCID: PMC6476948 DOI: 10.1297/cpe.28.25

Abstract

Hypertension is one of the most serious side effects of glucocorticoid therapy. We retrospectively investigated the frequency of hypertension during treatment of adrenal crisis and analyzed the factors associated with its development. Patients who were admitted for primary hypoadrenalism due to diagnosed or suspected adrenal crisis were included. In the analysis, the subjects were divided into two groups: the hypertensive group (group H) and non-hypertensive group (group Non-H). The primary endpoint was the difference in the hourly therapeutic hydrocortisone (HDC) dosage between the two groups. The hourly therapeutic HDC dose in the two groups was defined as the hourly HDC dose from the start of HDC infusion until the development of hypertension in group H or until the last blood pressure measurement in group Non-H. Nine of 19 crises led to hypertension. There was no significant difference in the therapeutic HDC dosage between the groups (p = 0.108). In conclusion, hypertension developed in some patients during treatment for adrenal crisis. There was no significant difference in the therapeutic HDC dosage between groups H and Non-H.

Keywords: adrenal crisis; hydrocortisone; hypertension; primary hypoadrenalism

References

  1. JAMA. 2002 Jan 9;287(2):236-40 - PubMed
  2. J Clin Endocrinol Metab. 2012 Dec;97(12):4429-38 - PubMed
  3. Am J Hypertens. 2016 Feb;29(2):266-72 - PubMed
  4. Eur J Endocrinol. 2016 Feb;174(2):177-86 - PubMed
  5. Clin Pediatr Endocrinol. 2015 Jul;24(3):77-105 - PubMed
  6. J Clin Endocrinol Metab. 2016 Feb;101(2):364-89 - PubMed

Publication Types